Seung Hyun Lee

Seung Hyun Lee

Auto-generated profile, based on publicly available information

Seung Hyun Lee

Department of Neurology, Jeju National University Hospital, Jeju National University College of Medicine, Jeju, South Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2020 in Journal of Movement Disorders
Verified
Journal Article
Open access
PDF file
KPKye Won Park
Kye Won Park
SJSungyang Jo
Sungyang Jo
SLSeung Hyun Lee
Seung Hyun Lee
YHYun Su Hwang
Yun Su Hwang
DLDagyo Lee
Dagyo Lee
MKMi Sun Kim
Mi Sun Kim
To investigate the efficacy of levodopa/carbidopa/entacapone (LCE) at bedtime for treating sleep disturbance in patients with Parkinson’s disease (PD) with motor fluctuations. Participants included 128 PD patients with motor fluctuations. All patients were assessed for motor, nonmotor, and sleep-specific symptoms using the United Parkinson’s Disease Rating Scale (UPDRS), the Korean version of the Nonmotor Symptom Scale, the Parkinson’s Disease Sleep Scale (PDSS), the Epworth Sleepiness Scale, and the Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ). We compared the baseline characteristics of patients with sleep disturbance (PDSS score < 120) and those without sleep disturbance (PDSS score ≥ 120). Thirty-nine patients with sleep disturbance who agreed to take LCE at bedtime completed 3-month follow-ups. We analyzed changes in the scores of motor, nonmotor, and sleep symptom scales over the 3 months. PD patients with sleep disturbance were at more advanced disease stages and had more severe motor, nonmotor, and sleep symptoms than those without sleep disturbance. Patients who took LCE at night showed improvements in motor (UPDRS part III, p = 0.007) and sleep symptoms (total PDSS, p < 0.001). Sleep features that benefitted from LCE included not only nocturnal motor components but also insomnia (PDSS items 2 and 3, p = 0.005 and p < 0.001) and rapid eye movement behavior disorder (PDSS item 6, p = 0.002; and RBDSQ, p < 0.001). The use of LCE at bedtime may be a useful treatment for sleep disturbance in advanced PD patients with motor fluctuations.

31 January 2023 in Journal of Movement Disorders
Verified
Journal Article
Open access
PDF file
KPKye Won Park
Kye Won Park
YHYun Su Hwang
Yun Su Hwang
SLSeung Hyun Lee
Seung Hyun Lee
SJSungyang Jo
Sungyang Jo
MKMi Sun Kim
Mi Sun Kim
Objective Associations between various metabolic conditions and Parkinson’s disease (PD) have been previously identified in epidemiological studies. We aimed to investigate the causal effect of lipid levels, type 2 diabetes mellitus (T2DM), and body mass index (BMI) on PD in a Korean population via Mendelian randomization (MR).Methods Two-sample MR analyses were performed with inverse-variance weighted (IVW), weighted median, and MR-Egger regression approaches. We identified genetic variants associated with lipid concentrations, T2DM, and BMI in publicly available summary statistics, which were either collected from genome-wide association studies (GWASs) or from meta-analyses of GWAS that targeted only Korean individuals or East Asian individuals, including Korean individuals. The outcome dataset was a GWAS on PD performed in a Korean population.Results From previous GWASs and meta-analyses, we selected single nucleotide polymorphisms as the instrumental variables. Variants associated with serum levels of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides, as well as with T2DM and BMI, were selected (n = 11, 19, 17, 89, and 9, respectively). There were no statistically significant causal associations observed between the five exposures and PD using either the IVW, weighted median, or MR-Egger methods (p-values of the IVW method: 0.332, 0.610, 0.634, 0.275, and 0.860, respectively).Conclusion This study does not support a clinically relevant causal effect of lipid levels, T2DM, and BMI on PD risk in a Korean population.

26 July 2022 in Journal of Movement Disorders
Verified
Journal Article
Open access
KWKyung Ah Woo
Kyung Ah Woo
HKHan Joon Kim
Han Joon Kim
SJSeung-Ho Jeon
Seung-Ho Jeon
HPHye Ran Park
Hye Ran Park
KPKye Won Park
Kye Won Park
BJBeomseok Jeon
Beomseok Jeon
Objective To investigate the long-term clinical outcomes of pallidal deep brain stimulation (GPi-DBS) in patients with pantothenate kinase-associated neurodegeneration (PKAN).Methods We reviewed the records of patients with genetically confirmed PKAN who received bilateral GPi-DBS for refractory dystonia and were clinically followed up for at least 2 years postoperatively at two centers in Korea. Pre- and postoperative Burke– Fahn–Marsden Dystonia Rating Scale motor subscale (BFMDRS-M) scores, disability subscale (BFMDRS-D) scores, and qualitative clinical information were prospectively collected. Descriptive analysis was performed for BFMDRS-M scores, BFMDRSD scores, and the orofacial, axial, and limb subscores of the BFMDRS-M at 6–12, 24–36, and 60–72 months postoperatively.Results Five classic-type, four atypical-type, and one unknown-type PKAN cases were identified. The mean preoperative BFMDRS-M score was 92.1 for the classic type and 38.5 for the atypical or unknown type, with a mean BFMDRS follow-up of 50.7 months and a clinical follow-up of 69.0 months. The mean improvements in BFMDRS-M score were 11.3%, 41.3%, and 30.5% at 6–12, 24–36, and 60–72 months, respectively. In four patients with full regular evaluations until 60–72 months, improvements in the orofacial, axial, and limb subscores persisted, but the disability scores worsened from 24–36 months post-operation compared to the baseline, mainly owing to the aggravation of eating and feeding disabilities.Conclusion The benefits of GPi-DBS on dystonia may persist for more than 5 years in PKAN. The effects on patients’ subjective disability may have a shorter duration despite improvements in dystonia owing to the complex manifestations of PKAN.

31 January 2023 in Journal of Movement Disorders
Verified
Journal Article
Open access
PDF file
YHYun Su Hwang
Yun Su Hwang
SJSungyang Jo
Sungyang Jo
KPKye Won Park
Kye Won Park
SLSeung Hyun Lee
Seung Hyun Lee
SLSangjin Lee
Sangjin Lee
MKMi Sun Kim
Mi Sun Kim
Objective Depression in Parkinson’s disease (PD) affects the quality of life of patients. Postural instability and gait disturbance are associated with the severity and prognosis of PD. We investigated the association of depression with axial involvement in early-stage PD patients.MethodsThis study involved 95 PD patients unexposed to antiparkinsonian drugs. After a baseline assessment for depression, the subjects were divided into a depressed PD group and a nondepressed PD group. Analyses were conducted to identify an association of depression at baseline with the following outcome variables: the progression to Hoehn and Yahr scale (H-Y) stage 3, the occurrence of freezing of gait (FOG), levodopa-induced dyskinesia, and wearing-off. The follow-up period was 53.40 ± 16.79 months from baseline.Results Kaplan–Meier survival curves for H-Y stage 3 and FOG showed more prominent progression to H-Y stage 3 and occurrences of FOG in the depressed PD group than in the nondepressed PD group (log-rank p = 0.025 and 0.003, respectively). Depression in drug-naïve, early-stage PD patients showed a significant association with the progression to H-Y stage 3 (hazard ratio = 2.55; 95% confidence interval = 1.32–4.93; p = 0.005), as analyzed by Cox regression analyses. In contrast, the occurrence of levodopa-induced dyskinesia and wearing-off did not differ between the two groups (log-rank p = 0.903 and 0.351, respectively).Conclusion Depression in drug-naïve, early-stage PD patients is associated with an earlier occurrence of postural instability. This suggests shared nondopaminergic pathogenic mechanisms and potentially enables the prediction of early development of postural instability.

1 January 2024 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
DKDong Hyun Kim
Dong Hyun Kim
TYTae Kyun Yoon
Tae Kyun Yoon
JCJae-Phil Choi
Jae-Phil Choi
SLSeung Hyun Lee
Seung Hyun Lee
Kim DH, et al. J Clin Neurol. 2024 Jan;20:e20. https://doi.org/10.3988/jcn.2023.0290

1 January 2021 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
KPKye Won Park
Kye Won Park
SLSeung Hyun Lee
Seung Hyun Lee
YHYun Soo Hwang
Yun Soo Hwang
KKKeon Woo Kim
Keon Woo Kim
KPKwan Young Park
Kwan Young Park
MKMi Sun Kim
Mi Sun Kim
Park KW, et al. J Clin Neurol. 2021 Oct;17(4):579-581. https://doi.org/10.3988/jcn.2021.17.4.579